ERBB2 and breast carcinoma: For the early stage setting of HR+/HER2+ breast cancer patients, the NA-PHER2 (a phase II, neoadjuvant study) evaluated a combination of Palbociclib, Fulvestrant, Trastuzumab and Pertuzumab in order to avoid the use of chemotherapy30.